Back to top

Image: Bigstock

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has BioCryst Pharmaceuticals (BCRX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

BioCryst Pharmaceuticals is one of 894 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BCRX is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for BCRX's full-year earnings has moved 9.36% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, BCRX has gained about 3.19% so far this year. At the same time, Medical stocks have lost an average of 2.74%. This means that BioCryst Pharmaceuticals is outperforming the sector as a whole this year.

Breaking things down more, BCRX is a member of the Medical - Drugs industry, which includes 172 individual companies and currently sits at #11 in the Zacks Industry Rank. On average, this group has lost an average of 12.04% so far this year, meaning that BCRX is performing better in terms of year-to-date returns.

BCRX will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BioCryst Pharmaceuticals, Inc. (BCRX) - free report >>

Published in